Xofigo

An Important Update on the Use of Radium in Combination with Zytiga and Xtandi

Make sure that you and your doctor use the bone-protecting approved medications (zoledronic acid or denosumab), especially for at least three weeks before using Xofigo (Radium-223).

Update on the Combination Use of Zytiga and Xofigo

Sub-group analysis of the clinical trial ERA 223 signal that the concerns about the use in combination of Zytiga and Xofigo might not cause a significant increase in the risk for developing bone fractures if a man is also simultaneously on a bone targeted therapy.

Predicting Survival During Radium-223 (Xofigo) Treatment 

In a small, 25 man, but significant clinical trial of men with metastatic castrate-resistant prostate cancer (mCRPC) who also qualified for Radium-223 (Xofigo) it was shown that the level of pain a man has during the treatment could be used as a prognostic tool of his survival.  

Xofigo (Radium-223) - Cautionary Information

The European Medicines Agency (EMA) has recommended that the use of Xofigo (Radium-223) be restricted.  The restrictions, because of safety and efficacy concerns in men with castrate resistant prostate cancer (mCRPC), include that Xofigo can be used only after two other treatments have been taken; when other therapies cannot be used and not in combination with other 2nd line hormone therapies. 

Warning - A Possible Danger - Xofigo in Combination with Zytiga and Prednisone

The European Medicines Agency (EMA) has recommended halting the use of the Xofigo (radium-223 dichloride) in combination with Zytiga (abiraterone acetate) and prednisone due to a possible increased risk of death and fractures.